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Dendritic Cells Transfected with Cytopathic
Self-Replicating RNA Induce Crosspriming
of CD8 T Cells and Antiviral Immunity
tory signals to naive T cells (Guermonprez et al., 2002).
The combination of these properties makes DCs particu-
larly suitable vehicles for antigens in vaccination strat-
egies.
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(Kleindienst and Brocker, 2003). Support for this as-
sumption comes from the observation that DCs internal-
ize antigens from dead or dying cells and reprocessSummary
them in the endosomal compartment or cytosol for pre-
sentation on their own MHC class I and class II mole-A potential shortcoming of nonlive vaccines is their
cules (Albert et al., 1998). Presentation of exogenousrelative inefficiency in generating T cell responses,
antigens via MHC class I has been termed crosspresen-thus limiting their application in infections requiring
tation because antigens that are not expected to gaincellular immunity. Here, we present a system to induce
access to the cytoplasm have “crossed” over to thecellular immunity and to study the immunological im-
endogenous antigen processing pathway. Although theplications of time-delayed dendritic cell (DC) apopto-
physiological contribution of crosspresentation to CD8sis and antigen reprocessing in vivo. We generated a
T cell priming during natural infections is still unclearself-replicating cytopathic pestivirus RNA to enhance
(Zinkernagel, 2002), it has been shown that the formationproduction and presentation of hepatitis C virus (HCV)
of MHC-peptide complexes and the immunogenicity of
antigens and to induce apoptosis in DC 24–48 hr after
antigens is enhanced when a protein is provided as part
transfection. Replicon-transfected H-2b DCs used to of a dying cell rather than as preprocessed peptides
immunize HLA-A2 transgenic mice induced protection (Albert et al., 1998; Inaba et al., 1998).
upon challenge with a vaccinia virus expressing HCV In efforts to integrate and translate this knowledge
antigens. Induction of cell death enhanced the immu- into rational vaccine design, we used DCs transfected
nogenicity of DC-associated antigen. Transfer of cellu- with cytopathic self-replicating RNA (replicon) to stimu-
lar material from vaccine DCs to endogenous antigen late virus-specific T cell responses in vivo. Specifically,
presenting cells was visualized in lymph nodes and we constructed a recombinant pestivirus replicon that
spleen, and crossprimed CD8 T cells were character- encodes the complete hepatitis C virus nonstructural
ized. The findings are relevant for the rational design of protein 3 (HCVNS3) and combines the ability to amplify
vaccines against noncytopathic pathogens like HCV. itself in transfected cells with the ability to induce apo-
ptosis. This dual function resulted in enhanced produc-
Introduction tion, processing, and presentation of the encoded
HCVNS3 antigen and in time-delayed cell death in vivo
with subsequent reprocessing and crosspriming of DC-Enhancing CD8 T cell priming to nonliving antigens, a
associated antigens.major goal for the generation of vaccines against patho-
As a model antigen, we chose the NS3 protein ofgens and cancers, has proven exceedingly difficult.
HCV for several reasons. First, given the global diseaseMany laboratories try to exploit the natural and unique
burden and public health impact of HCV infection, aabilities of DCs to induce and regulate immunity (Ban-
protective or therapeutic vaccine would be highly desir-chereau and Steinman, 1998; Steinman et al., 2003).
able (Davis et al., 2003). Second, HCV clearance andAfter antigen acquisition, DCs migrate to secondary
protective immunity are associated with strong, durablelymphoid organs where they present processed immu-
T cell responses against multiple HCV epitopes (Nascim-nogenic peptides in the context of major histocompati-
beni et al., 2003; Shoukry et al., 2003; Thimme et al.,bility complexes (MHCs) and deliver critical costimula-
2001), whereas HCV-specific antibodies can disappear
after recovery (Takaki et al., 2000) and do not to contrib-
*Correspondence: rehermann@nih.gov
ute to immune protection (Nascimbeni et al., 2003;4 Present address: Fox Chase Cancer Center, Philadelphia, Pennsyl-
Shoukry et al., 2003). Third, HCVNS3 harbors some of thevania 19111.
most frequently targeted and highly conserved CD45 Present address: Department of Immunology, Duke University
Medical School, Durham, North Carolina 27710. (Diepolder et al., 1995) and CD8 T cell epitopes (Takaki
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et al., 2000). Fourth, HCV is a tissue-tropic, noncyto- 1C) by electroporation. Efficiency of transfection, RNA
replication, and HCVNS3 expression were monitored bypathic virus that does not infect professional antigen
presenting cells (APCs) and rarely induces death of in- flow cytometry, immunofluorescence (IF) microscopy,
and Western blot (Figures 1D–1G). After transfectionfected cells, thus reducing the main source of exoge-
nous antigens for crosspresentation. Poor priming of with cytopathic Repl-HCVNS3 RNA, almost the entire DC
population (95%–100%) expressed high levels of HCVNS3cellular immune response is therefore regarded as an
important reason for the high incidence of HCV persis- (Figures 1D and 1E) homogenously distributed in the
cytoplasm (Figures 1F and 1G). This level was similartence (Thimme et al., 2001). Because of these observa-
tions, an experimental strategy that forces exogenous to that of other bicistronic replicon constructs tested in
different cell lines, i.e., in the range of approximatelyantigens into the MHC class I pathway and promotes
crosspresentation could be particular important to gen- 100 ng protein per 107 cells (Tautz et al., 1999). Lower
level of antigen expression was instead achieved aftererate effective T cell responses against HCV.
Using a murine H-2b DC line and HLA-A2 transgenic transfection with noncytopathic Repl-HCVNS3 RNA (Fig-
ures 1D and 1E). RNA replication was confirmed whenmice, we demonstrate that a single injection of DCs
transfected with cytopathic replicon RNA induced effi- DC2.4 transfected with RNAs encoding a defective
BVDV replicase revealed no staining (data not shown).cient T cell responses that conferred antiviral immunity.
We also show the relevance of the crosspriming path- This was consistent with previous reports that showed
replicon-mediated protein synthesis only in the pres-way for CD8 T cell activation and the participation of
host APCs in this process. ence of RNA replication (Behrens et al., 1998).
Cytopathic Repl-HCVNS3 RNA Induces ApoptosisResults
of Transfected DCs
To study the immunologic implications of DC apoptosisCytopathic and Noncytopathic Self-Replicating RNAs
Encoding HCVNS3 Can Be Originated from the Bovine and antigen reprocessing, the survival kinetics of DC2.4
were compared after transfection with cytopathic orViral Diarrhea Virus Genome
To produce an antigen expression system, we generated a noncytopathic Repl-HCVNS3 RNA. Major differences were
revealed on examination of the cultures by light micros-self-replicating positive-strand viral RNA (replicon) from
the genome of the pestivirus bovine viral diarrhea virus copy. Floating cells appeared in the DC2.4 cultures
within 1 or 2 days after transfection with cytopathic(BVDV; Figure 1A). This recombinant bicistronic repli-
con, termed Repl-HCVNS3, contains a 5 terminal open Repl-HCVNS3 RNA, and, after that, the cultures turned
into single cell suspensions containing loose clumps ofreading frame (ORF), encoding a fusion protein of the
pestiviral autoprotease Npro (Wiskerchen et al., 1991) and large, dendritic-shaped cells. In contrast, in the cultures
transfected with noncytopathic Repl-HCVNS3 RNA, cellsthe heterologous antigen HCVNS3, and a 3 terminal ORF,
encoding the BVDV nonstructural proteins (Figure 1A). remained as adherent and proliferative as nontrans-
fected control cells, and cell detachment started onlyWhen transfected into host cells, Repl-HCVNS3 RNA op-
erates initially as mRNA. Translation of the ORFs is medi- after prolonged culture. To more rigorously explore the
mechanisms of cell death, we monitored DC surfaceated by internal ribosomal entry sites (IRES) located in
the BVDV 5 untranslated region and downstream of the expression of phosphatidylserine and uptake of propid-
ium iodide as well as DNA fragmentation. As depictedHCVNS3 coding region. Translation products are co- and
posttranslationally processed by viral and cellular prote- in Figure 2, the percentage of Annexin V- and TUNEL-
positive apoptotic cells as well as the percentage ofases into mature proteins. In particular, the authentic
N terminus of HCVNS3 is generated by autoproteolytic propidium iodide-positive dead cells increased over
time after transfection with cytopathic Repl-HCVNS3 RNAcleavage of Npro. The BVDV nonstructural proteins are
active components of the viral replication complex that but not after transfection with noncytopathic Repl-
HCVNS3 RNA. Induction of apoptosis and cell death was,multiplies the RNA copies in the cytoplasm via negative-
strand intermediates (Behrens et al., 1998; Grassmann therefore, clearly dependent upon the cytopathic effect
of the replicon and the time after transfection and notet al., 2001). Importantly, production of BVDVNS3 as a
single protein (cytopathic Repl-HCVNS3) rather than as a due to the electroporation itself.
part of the uncleaved BVDVNS2-3 polypeptide (noncyto-
pathic Repl-HCVNS3) is the molecular correlate for the DCs Transfected with Cytopathic Repl-HCVNS3 RNA
cytopathogenicity observed for the replicon in cell cul- Induce Crosspriming of HCVNS3-Specific CD8 T Cells
ture as well as for BVDV in the natural infection (Thiel To assess their in vivo-priming capacity, DC2.4 trans-
et al., 1996). fected with cytopathic or noncytopathic Repl-HCVNS3
RNA were subcutaneously (s.c.) injected into HLA-A2-
transgenic mice. Importantly, the yield of apoptotic andCytopathic Repl-HCVNS3 RNA Induces High Levels
of HCVNS3 Expression in Transfected DCs dead cells was still negligible at the time of injection. By
adoptively transferring H-2b cells into mice that expressInduction of effective T cell responses depends on the
amount of antigen delivered and the number and type both murine H-2b and human HLA-A2 alleles, we were
able to specifically address the impact of crosspresen-of APCs that actively process and present the antigen.
To provide cytoplasmic HCVNS3 protein for antigen pro- tation of exogenous cell-associated antigens on in vivo
priming of CD8 T cells. When the injected DC2.4 di-cessing and presentation, we introduced in vitro-tran-
scribed cytopathic or noncytopathic Repl-HCVNS3 RNA rectly prime HCVNS3-specific CD8 T cells, this protocol
results in the expansion of H-2b-restricted T cells. On(Figure 1B) into DC2.4 lines (Shen et al., 1997) (Figure
Cytopathic Self-Replicating RNA in Dendritic Cells
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Figure 1. Generation and Characterization of Cytopathic and Noncytopathic Repl-HCVNS3 RNA
(A) Schematic diagram of the bovine viral diarrhea virus (BVDV) genome and in vitro-transcribed cytopathic and noncytopathic BVDV-derived,
bicistronic self-replicating RNA constructs encoding HCVNS3 (Repl-HCVNS3 RNA). The 5 terminal ORF consists of the BVDV Npro coding region
and the HCVNS3 gene in both constructs. The Npro coding region is important for efficient BVDV IRES function and contains the natural start
codon for translation; the HCVNS3 (gray box) replaces the BVDV structural regions and ends with an artificial translation stop codon. The 3
terminal ORF, located downstream of the EMCV (encephalomyocarditis virus) IRES, encodes the BVDV nonstructural proteins and differs
between the two constructs. The ubiquitin unit (ubi) and the 3 terminal part of the BVDV p7-coding gene (p7) provide cleavage sites for the
generation of the authentic N terminus of the BVDVNS3 and the BVDVNS2-3 proteins, respectively. A, autoprotease; filled arrow, viral protease;
open arrow, cellular protease.
(B) Agarose gel electrophoresis of in vitro transcribed cytopathic (lane 1) and noncytopathic (lane 2) Repl-HCVNS3 RNA.
(C) Morphology of cultured DC2.4.
(D and E) Efficiency of DC2.4 transfection with cytopathic (lane 2 and black histogram area) or noncytopathic (lane 3 and gray histogram area)
Repl-HCVNS3 RNA as determined by Western blot and flow cytometry for HCVNS3 protein. Lane 1 and open area, untransfected DC2.4.
(F and G) HCVNS3-specific indirect IF microscopy of DC2.4 transfected with cytopathic Repl-HCVNS3 RNA.
the contrary, when host resident APCs prime HCVNS3- CD8T cells was determined 1 week after a single immu-
nization in ex vivo IFN-ELISpot assays in which purifiedspecific CD8 T cells (as a consequence of reprocessing
and crosspresentation of antigens acquired from apo- splenic T cells were stimulated with either C1R-AAD
(HLA-A2) or EL4 (H-2b) cells in the presence of individualptotic or dead DC2.4), this protocol results in the expan-
sion of H-2b- and HLA-A2-restricted T cells. Thus, HLA- peptide pools covering the complete HCVNS3 sequence.
The peptide pools did not crossreact, because H-2b-A2-restricted T cell responses can only be induced by
crosspriming. restricted T cells from C57BL/6 mice immunized with
cytopathic Repl-HCVNS3 RNA-transfected DC2.4 did notThe frequency of the in vivo-primed HCVNS3-specific
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EL4 target cells. As shown in Figure 4, CTL responses
obtained by immunization with cytopathic Repl-HCVNS3
RNA-transfected DC2.4 were significantly stronger than
those obtained by immunization with DC2.4 transfected
with noncytopathic Repl-HCVNS3 RNA (p  0.05) or with
a single i.m. injection of plasmid DNA (p  0.05). CTL
activities were detected against HLA-A2 and H-2b target
cells pulsed with all three HCVNS3 peptide pools, thus
confirming the ELISpot results and the contribution of
crosspriming to the in vivo induction of CD8 T cell re-
sponses.
Cell Death Enhances Immunogenicity
of DC-Associated HCVNS3 Antigen
We further evaluated the relative contribution of cell
death to the immunogenicity of the DC-associated anti-
gens. Because the HCVNS3 expression level differed be-
tween DC2.4 transfected with cytopathic or noncyto-
pathic Repl-HCVNS3 RNA, we performed the following
experiment. We compared the priming capacity of
DC2.4 transfected with noncytopathic Repl-HCVNS3 RNA
with that of DC2.4 transfected with noncytopathic Repl-
HCVNS3 RNA and supertransfected 48 hr later with a
cytopathic replicon encoding the irrelevant antigen glu-
coronidase instead of HCVNS3 (cytopathic Repl-GUS
RNA). Although the level of HCVNS3 expression was
equivalent in both immunization regimens, the induced
CD8 T cell responses differed. Number and cytotoxic
activity of CD8 T cells were significantly enhanced in
mice s.c. injected with supertransfected DCs (p  0.04;
Figures 3 and 4). Notably, this increase was exclusively
observed for the HLA-A2-restricted T cell response re-
flecting crosspriming.
Resident Host APCs Internalize Cellular Fragments
of Injected DC2.4 Transfected with Cytopathic
Repl-HCVNS3 RNA
To study the fate of injected DCs and to visualize the
transfer of cell-associated antigens that underlies cross-
priming in vivo, cytopathic Repl-HCVNS3 RNA-trans-
Figure 2. Kinetic of Apoptosis of DC2.4 Transfected with Cytopathic fected DC2.4 were labeled with CFSE and s.c. injected
or Noncytopathic Repl-HCVNS3 RNA into HLA-A2-transgenic mice. Twelve hours after injec-
(A) Annexin V/propidium iodide (PI) double staining. tion, draining lymph nodes and spleen were isolated
(B) TUNEL assay. and analyzed for the presence of CFSE fluorescence.
Although a distinct, CFSE-positive cell population was
found in the lymph nodes, the green fluorescence wasrecognize these peptides on HLA-A2-positive APCs
(data not shown). As shown in Figure 3, immunization rarely homogenously distributed in intact, live cells (Fig-
ure 5A). Instead, it was almost exclusively detected inwith cytopathic Repl-HCVNS3 RNA-transfected DC2.4 in-
duced a substantial number of IFN--producing T cells the form of cellular fragments in the cytoplasm (Figure
5B) of HLA-A2-positive (Figure 5E) cells, indicating thatdirected against all three HCVNS3 peptide pools. HLA-
A2-restricted T cell responses were as vigorous as H-2b- these were not the injected DC2.4 but host cells that had
captured cellular fragments of the injected, apoptoticrestricted T cell responses, thus indicating the relevance
of crosspriming. An equivalent response could neither DC2.4. Their CD11c negative and F4/80 positive pheno-
type (Figure 5E) and their location in the marginal zonebe achieved with DC2.4 transfected with noncytopathic
Repl-HCVNS3 RNA (p0.04) nor with a single intramuscu- of the spleen (Figure 5C) indicate that the majority of
these host cells were macrophages.lar (i.m.) injection of plasmid DNA encoding HCVNS3
(p  0.04). When the same experiments were performed with
DC2.4 transfected with noncytopathic Repl-HCVNS3 RNA,To measure the cytotoxic activity of the in vivo-primed
HCVNS3-specific CD8 T cells, purified splenic T cells both size and phenotype of the CFSE-positive HLA-
A2-positive host cell population differed. More CFSE-from immunized mice were in vitro restimulated with
either C1R-AAD (HLA-A2) or EL4 (H-2b) cells in the pres- positive cells in the lymph nodes were HLA-A2-negative
and the HLA-A2-positive cells displayed a CD11cence of individual HCVNS3 peptide pools and, after 7
days, tested for lysis of peptide-pulsed C1R-AAD and rather than CD11c phenotype.
Cytopathic Self-Replicating RNA in Dendritic Cells
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Figure 3. Analysis of Directly Primed and Crossprimed HCVNS3-Specific IFN--Secreting CD8 T Cells
HLA-A2- and H-2b-restricted CD8 T cells of immunized HLA-A2-transgenic mice were quantitated with peptide-loaded C1R-AAD (HLA-A2)
(filled squares) and EL4 (H-2b) cells (open circles), respectively. HLA-A2-restricted CD8 T cells are crossprimed; H-2b-restricted CD8 T cells
are either directly primed or crossprimed (left three columns). Direct priming and crosspriming cannot be differentiated after immunization
with naked plasmid DNA (right column). Each data point represents the HCVNS3 peptide pool-specific response (mean  SD) of six to ten mice
[p  0.04 for DC/cytopathic Repl-HCVNS3 RNA versus naked plasmid HCVNS3 DNA; p  0.04 for DC/cytopathic Repl-HCVNS3 RNA versus DC/
noncytopathic Repl-HCVNS3 RNA at 2.5 and 5  105 T cells/well; p  0.05 for (DC/noncytopathic Repl-HCVNS3 RNA  cytopathic Repl-GUS
RNA) versus DC/noncytopathic Repl-HCVNS3 RNA at 5  105 T cells/well for HLA-A2-restricted responses only].
DCs Transfected with Cytopathic Repl-HCVNS3 RNA showed a vigorous proliferative response to recombi-
nant HCVNS3 protein, which was significantly strongerInduce HCVNS3-Specific CD4 T Cell Responses
Effective induction of CD4 T cell responses is an impor- than those induced by DC2.4 transfected with noncyto-
pathic Repl-HCVNS3 RNA (p 0.002) and by conventionaltant component of any vaccination strategy because
maintenance of CD8 T cell responses often requires i.m. DNA immunization (p  0.002).
CD4 T cell help. In parallel with the CD8 T cell analysis,
the potential of DCs transfected with noncytopathic DCs Transfected with the Cytopathic Repl-HCVNS3
RNA Induce Protective Antiviral Immunityand/or cytopathic replicons to induce CD4 T cell re-
sponses in vivo was compared in HLA-A2-transgenic Because HCV does not infect rodents, we used a pre-
viously described surrogate challenge model (Wede-mice. As demonstrated in Figure 6, T cells isolated from
draining lymph nodes and spleen of mice immunized meyer et al., 2001) to assess the protective capacity of
the induced T cells in vivo. Three weeks after a single s.c.with cytopathic Repl-HCVNS3 RNA-transfected DC2.4
Immunity
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Figure 4. Analysis of Directly Primed and Crossprimed HCVNS3-Specific Cytotoxic CD8 T Cells
HLA-A2- and H-2b-restricted cytotoxic CD8 T cell responses of immunized HLA-A2-transgenic mice were measured against peptide-pulsed
C1R-AAD (filled squares) or EL4 (open circles) targets. HLA-A2-restricted CD8 T cells are crossprimed; H-2b-restricted CD8 T cells are either
directly primed or crossprimed (left three columns). Direct priming and crosspriming cannot be differentiated after immunization with naked
plasmid DNA (right column). Each data point represents the HCVNS3 peptide pool-specific response of six to ten mice (mean  SD) [p  0.05
for DC/cytopathic Repl-HCVNS3 RNA versus naked plasmid HCVNS3 DNA; p  0.05 for DC/cytopathic Repl-HCVNS3 RNA versus DC/noncytopathic
Repl-HCVNS3 RNA at 30:1, 60:1, and 120:1 E:T for HLA-A2-restricted responses only; p  0.04 for (DC/noncytopathic Repl-HCVNS3 RNA 
cytopathic Repl-GUS RNA) versus DC/noncytopathic Repl-HCVNS3 RNA at 60:1 and 120:1 E:T for HLA-A2-restricted responses only].
immunization with DC2.4 transfected with cytopathic ure 7A). Nonspecific responses did not significantly con-
tribute to the antiviral protection as we determined in aor noncytopathic Repl-HCVNS3 RNA, HLA-A2-transgenic
mice were intraperitoneally challenged with 107 pfu re- control vaccination experiment with DC2.4 transfected
with cytopathic Repl-GUS RNA (data not shown).combinant vaccinia virus encoding HCVNS3. In parallel,
a control group of mice was immunized with 100 	g
plasmid DNA encoding HCVNS3 and challenged with the Discussion
same type and dose of vaccinia virus. Five days after
challenge, mice were sacrificed, vaccinia virus titers Delivery of antigens to DCs in the form of cytopathic
self-replicating RNA induces and specifically promoteswere determined, and cellular immune responses ana-
lyzed. As shown in Figure 7A, the group of mice immu- exogenous antigen presentation and crosspriming in
vivo. The potency of this strategy is documented by thenized with DC2.4 transfected with cytopathic Repl-
HCVNS3 RNA displayed lower vaccinia virus titers than demonstration that a single s.c. immunization induced
fully competent antigen-specific T cells and protectedthe group of mice immunized with DC2.4 transfected
with noncytopathic Repl-HCVNS3 RNA or with naked plas- mice in a surrogate challenge model. The elicited anti-
gen-specific CD4 and CD8T cell response was signifi-mid DNA. The adjuvant effect of cell death was con-
firmed by the intermediate level of protection displayed cantly stronger than that induced by conventional i.m.
DNA vaccination.by mice immunized with DC2.4 transfected with noncy-
topathic Repl-HCVNS3 RNA and supertransfected with
cytopathic Repl-GUS RNA. Protection correlated with What Are the Advantages of Using Self-Replicating
RNA and in Particular Pestivirus-Derived Repliconsthe strength of the T cell response to pools of overlap-
ping HCVNS3 peptides (Figure 7A) and to the HLA-A2- for Antigen Delivery to DCs?
First, due to its autonomous replication ability, the sub-restricted minimal optimal HCV epitopes (Figure 7B) and
not with the response to the vaccinia virus epitope (Fig- genomic BVDV-derived vector significantly increases
Cytopathic Self-Replicating RNA in Dendritic Cells
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Figure 5. Localization of Injected DC2.4 Transfected with Cytopathic or Noncytopathic Repl-HCVNS3 RNA
Twelve hours after injection of CFSE-labeled Repl-HCVNS3 RNA-transfected DC2.4, draining lymph nodes and spleens of HLA-A2-transgenic
mice were examined for the presence of CFSE (green) by IF microscopy and flow cytometry.
(A and B) Intact CFSE-labeled DC2.4 (A) and CD11c (red) host DCs containing green fragments (B) in the low-density lymph node cell fraction
of mice immunized with cytopathic Repl-HCVNS3 RNA-transfected DC2.4.
(C and D) CFSE and CD11c fluorescence (red) in the marginal zone of spleen cryosections of representative experimental (C) and control (D) mice.
(E) Phenotype of CFSE-positive cells detected in low-density lymph node and spleen cell populations of groups of three mice.
Immunity
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double-stranded RNA intermediates, which are known
to induce DC maturation, MHC expression, and cytokine
production (Cella et al., 1999).
Second, self-replicating RNA allows high-level ex-
pression and endogenous processing of the encoded
antigens in DC, thus overcoming one of the main limiting
factors in the priming of T cell responses. Both factors
provide an advantage over the use of nonreplicating
RNA (Saeboe-Larssen et al., 2002) and peptide-loaded
DC (Dhodapkar et al., 1999).
Third, the cytopathic effect of the self-replicating RNA
triggers time-delayed apoptosis of the vaccine DCs in
vivo, allowing sufficient time for migration to secondary
lymphoid organs. Although direct uptake of self-replicat-
ing RNA by host DC and endogenous neosynthesis of
HCVNS3 can not formally be excluded (Freigang et al.,
2003), the reprocessing of dying DCs by recipient APCs
is likely to play an important, if not essential, role in
enhancing antigen-specific activation, expansion, and
proliferation of T cells. Direct experimental evidence
of crosspriming in the cytopathic Repl-HCVNS3 system
is the demonstration of functional, HLA-A2-restricted
T cells in AAD-transgenic mice immunized with Repl-
HCVNS3 RNA-transfected H-2b DCs (Figures 3 and 4).
Indirect evidence is the visualization of cellular frag-
ments of injected DCs in resident host APCs (Figure 5B).
The level of antigen expression and tissue damage
appear to be crucial factors in the crosspresentation
and crosspriming process. Under normal circumstances,
when antigen levels are within the physiologic range
and no significant tissue damage occurs, crosspresen-
tation is probably less efficient than direct presentation,
because it requires the additional step of antigen trans-Figure 6. HCVNS3-Protein-Specific CD4 T Cell Proliferation
fer from one cell to another (Zinkernagel, 2002). MostStimulation index (mean  SD) of lymph node and spleen cells of
model systems that describe crosspresentation there-groups of six to ten immunized HLA-A2-transgenic mice.
fore use high levels of antigen expression (Heath and
Carbone, 2001). Our results, however, show that induc-
tion of cell death (by the cytopathic Repl-GUS RNA) can
the level of antigen expression in transfected DCs. It help to overcome the limitations of low antigen levels
therefore requires significantly less input of nucleic acid in noncytopathic Repl-HCVNS3 RNA-transfected DCs in
than conventional transfection methods. Second, the the priming of cellular immune responses. Interestingly,
RNA amplification process is programmed entirely by a recent publication identified endogenous factors, re-
the replicon genome and occurs exclusively in the cyto- leased by injured and dying cells, as the molecular corre-
plasm of the transfected cell. Because of the lack of the lates for the enhanced immunogenicity of antigens asso-
regions encoding viral structural proteins, replication is ciated with injured and dying cells (Shi et al., 2003).
not linked to the formation of progeny virus particles The transfer of antigens from the injected cells to the
and, therefore, secondary infection of other cells cannot APCs of the host may occur either in the periphery or
occur. Third, the RNA replication process bypasses any in the secondary lymphoid organs. The first scenario
involvement of the cellular transcription machinery and occurs when antigen-expressing, nonmigratory cells are
its regulatory factors. Fourth, the absence of a nuclear injected (Berd, 2001). It is also characteristic for i.m.
transcription step avoids unpredictable effects of nu- naked DNA (Gurunathan et al., 2000) and RNA (Ying et
clear splicing, and the use of viral promoters eliminates al., 1999) immunization and is biologically disadvanta-
the need for chromosomal integration and its potential geous, because additional inflammatory signals are re-
complications. Finally, pestivirus-derived vectors pro- quired to attract and activate migratory DCs (Guruna-
vide an extra margin of safety over other viral-based than et al., 2000) and because only a small fraction of
systems, such as those derived from Flavi- and alpha- exogenous cell-associated antigen is eventually taken
viruses (Khromykh, 2000; Leitner et al., 2003), because up and transported to the regional lymph nodes. In the
pestiviruses do not infect humans (Lindenbach and second case, the injected DCs actively migrate to the
Rice, 2001). draining lymph nodes or spleen and undergo apoptosis
in these secondary lymphoid organs. Although we can-
not completely exclude the possibility that dying DC2.4What Are the Mechanisms Underlying the Enhanced
Immunogenicity of DCs Transfected with Cytopathic are taken up by host migratory cells in the periphery,
the second scenario appears to be more likely in ourSelf-Replicating RNA?
First, self amplification of the transfected RNA in DCs study because s.c.-injected DCs only need 6 hr to ap-
pear in the draining lymph nodes (Figure 5A, Mueller etmimics viral infection and results in the synthesis of
Cytopathic Self-Replicating RNA in Dendritic Cells
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Figure 7. Protective Immune Response upon
Viral Challenge
(A) Viral titers and HCV- and VV-specific CD8
T cell responses of groups of five immunized
HLA-A2-transgenic mice challenged with re-
combinant HCVNS3-encoding VV. Dotted line,
detection limit of the assay.
(B) Frequency of HLA-A2-restricted IFN--
producing CD8 T cells in HLA-A2-transgenic
and wild-type mice immunized with cyto-
pathic Repl-HCVNS3 RNA-transfected DC2.4.
al., 2002). The replicon-transfected DC2.4 did not show into the crosspriming pathway might be especially use-
ful for rational vaccine design against pathogens that doany sign of apoptosis within the first 12 hr after transfec-
tion (Figure 2), maintained the capacity to mature and not induce significant immune responses during natural
infection. The high rate of HCV persistence, for example,migrate (Okada et al., 2001), and therefore have suffi-
cient time to reach the lymph nodes prior to undergoing might be attributable to the noncytopathic nature of the
virus and to the subsequent absence or scarcity of virus-apoptosis. Although, in principle, any cell could be trans-
fected with the replicon RNA, it might therefore be advis- infected apoptotic or dead cells as source of exogenous
antigen. In addition, HCV does not replicate efficientlyable to use DCs that maintain their own migratory ability
and transport the antigen directly to secondary lymphoid in APCs and may even have developed means to impair
their function (Bain et al., 2001). Under those circum-organs.
Our study also provides relevant information on the stances, the crosspriming pathway can be exploited
to therapeutically induce responses that are difficult toidentity of the endogenous APCs that take up antigen
from the injected DCs. Although these cells have fre- generate otherwise.
quently been described as professional APC (Bevan,
Experimental Procedures1987) and of bone marrow origin (Huang et al., 1994),
their specific phenotype is not known. In vitro studies
Cell Lines
have described that DCs (Albert et al., 1998; Rock et The immature murine DC2.4 line (C57BL/6 origin, H-2b haplotype)
al., 1990; Sigal et al., 1999), macrophages (Kovacsovics- (Shen et al., 1997), generously provided by Dr. K.L. Rock and the
Dana Farber Cancer Institute (Boston, MA), was grown in completeBankowski et al., 1993; Ramirez and Sigal, 2002), and
RPMI 1640 medium (10% heat-inactivated fetal bovine serum [FBS],even B cells (Barnaba et al., 1990) are able to cross-
2 mM L-glutamine, 100 	M nonessential amino acids, 100 U/mlpresent antigens under specific conditions. In vivo stud-
penicillin, 100 	g/ml streptomycin) containing 50 	M 2-mercapto-ies, however, show CD8 DCs as the major cell popula-
ethanol (Gibco BRL, Grand Island, NY). This DC line has the full
tion responsible for crosspriming (den Haan et al., 2000; functional capacity of primary DC, including the capacity to mature,
Pooley et al., 2001). Interestingly, in our experiments, to process antigens, to upregulate expression of MHC I and II mole-
cules as well as CD80, CD86, CD40, CD54, and to migrate (Okadaonly a small fraction of the host cells that contained
et al., 2001). The HLA-A, B-negative human B lymphoblastoid cellcellular components of injected DCs expressed the
line C1R transfected with AAD (a hybrid MHC class I molecule con-CD11c phenotype. The large majority of cells were, on
sisting of the 
1  
2 domains of HLA-A2.1 and the 
3 domain ofthe contrary, CD11c negative and F4/80 positive, sug-
H-2Dd) (Newberg et al., 1996) was provided by Dr. J. Berzofsky
gesting that macrophages, in addition to DCs, might (National Institutes of Health, Bethesda, MD) and propagated in
play a major role in antigen uptake and crosspriming. complete medium with 400 	g/ml G418 (Sigma-Aldrich, St. Louis,
MO) without 2-mercaptoethanol. The murine H-2b thymoma cell lineIn conclusion, an experimental trick to force antigen
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EL4 and the human osteosarcoma cell line 143TK (ATCC, Rockville, min incubation on ice, cells were seeded in fresh complete medium
and incubated at 37C and 5% CO2.MD) were grown in complete DMEM (Gibco BRL, Grand Island, NY)
medium in the presence or absence of 50	M 2-mercaptoethanol, re- Transfection efficiency was evaluated after 24 or 48 hr of culture.
For indirect IF microscopy and flow cytometry, transfected cellsspectively.
were fixed on chamber slides or in tubes, permeabilized, and incu-
bated with 1B6 anti-HCVNS3 (Wolk et al., 2000), followed by fluores-Recombinant Proteins and Synthetic Peptides
cein isothiocyanate (FITC)-conjugated F(ab)2 anti-mouse IgG (Cal-Recombinant HCVNS3 protein (aa 1192–1457 of HCV-1 genotype 1a;
tag Laboratories, Burlingame, CA). For Western blot analysis,gene bank accession number M62321) was kindly provided by Dr.
transfected and untransfected DC2.4 lysates were subjected toM. Houghton (Chiron Corporation, Emeryville, CA). One hundred
SDS-polyacrylamide gel electrophoresis (SDS-PAGE), transferredtwenty-six pentadecamer peptides (Mimotopes, Clayton, Australia),
onto Immobilon-P membranes (Millipore, Bedford, MA), and immu-overlapping by ten amino acids each and spanning the complete
noblotted using 1B6 anti-HCVNS3 and horseradish peroxidase-conju-amino acid sequence of the HCVNS3 protein, were divided into three
gated anti-mouse Ig, followed by enhanced chemiluminescencepools designated pool 1 (aa 1021–1240), pool 2 (aa 1231–1443), and
(ECL; Amersham, Arlington Height, IL).pool 3 (aa 1434–1660) at 24	g/ml per peptide. The HLA-A2 restricted
minimal optimal epitopes HCV NS31073–1081 CVNGVCWTV, NS31084–1092
Cell Death AnalysisGAGTRTIAS, NS31169–1177 LLCPAGHAV, NS31406–1415 KLVALGINAV,
Replicon-induced apoptosis of transfected DC2.4 was demon-NS31585–1593 YLVAYQATV (Major et al., 2001), and the vaccinia virus
strated by annexin V/propidium iodide double staining (Annexinepitope SLSAYIIRV (Drexler et al., 2003) were synthesized at 80%
V-FITC Apoptosis Detection Kit I, PharMingen, San Diego, CA) andpurity at Research Genetics (Huntsville, AL) or at the Facility for
TUNEL assay (DeadEnd Fluorimetric TUNEL System, Promega,Biotechnology Resources, Center for Biologics Evaluation and Re-
Madison, WI) followed by flow cytometry.search, Food and Drug Administration (Bethesda, MD).
Mouse ImmunizationConstruction of Recombinant Plasmids
H-2b C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME) and AAD-The plasmid encoding cytopathic Repl-HCVNS3 was generated by
transgenic mice (HLA-A2 on H-2b C57BL/6 background) (Newberg etmodifying the original, GUS-expressing cDNA construct Bi-ubi-NS3-
al., 1996), kindly provided by Dr. V. Engelhard (University of Virginia,NS5B (Tautz et al., 1999). First, g at position 12290 (numbering refers
Charlottesville, VA), were used under a protocol approved by theto the sequence of the BVDV CP7 construct; Meyers et al., 1996) was
Animal Care and Use Committee of the National Institute of Diabetessubstituted (Quickchange procedure) by c to introduce an additional
and Digestive and Kidney Diseases. For DC-immunization, DC2.4SrfI restriction site at the immediate 3 end of the RNA coding region.
were harvested 12 or 48 hr after transfection with cytopathic orThis change allowed the generation of the authentic 3-terminus in
noncytopathic Repl-HCVNS3, washed twice, and resuspended inrunoff viral RNA transcripts from the linearized cDNA construct.
PBS. For selected immunizations, 5  105 transfected DC2.4 wereSecond, tcc at position 896-898 (BVDV CP7; Meyers et al., 1996)
labeled with 5 	M CFSE (Molecular Probes) at 37C for 10 min andwas exchanged (Quickchange procedure) into gca to introduce an
washed once with PBS/0.1% FCS and twice with PBS. TransfectedFspI restriction site at the 3 end of the BVDV Npro coding region.
DC2.4 (500,000) in PBS (100 	l) were s.c. injected (base of tail) intoThe resulting plasmid was termed Bi-ubi-NS3-NS5B (Fsp). Third,
6- to 8-week-old female mice. For DNA immunization, 50	g pcDNA/the HCVNS3 gene was amplified by PCR from the HCV Con1 cDNA
NS3 was injected into each regenerating tibialis anterior muscle 5isolate (Lohmann et al., 1999) using a sense primer (5-caagctgcg
days after i.m. injection of 10 	M cardiotoxin.cacctattacggcc-3) with an FspI restriction site and an antisense
primer (5-gtacatcgatatcgtcgactacgtgacgacctcca-3) with an artifi-
cial stop codon and additional SalI and ClaI restriction sites. The Primary Cell Preparations
PCR product was sequenced and cloned via FspI and ClaI (position Mice were sacrificed 7 days after immunization. Draining lymph
11083 of BVDV CP7 in the NS5B coding region) into Bi-ubi-NS3- nodes and spleens were isolated, injected with 400 	g/ml Liberase
NS5B (Fsp). The resulting plasmid was digested with NheI (cutting CI (Roche Diagnostics, Indianapolis, IN), incubated at 37C for 30
upstream of the SP6 promoter) and SalI (cutting downstream of the min, and forced through a cell strainer (Falcon, Franklin Lakes, NJ)
inserted HCVNS3 gene) to obtain a DNA fragment consisting of the to obtain single cell suspensions. T cells were isolated with anti-
BVDV 5UTR and the Npro coding region fused in frame to the HCVNS3 CD90 (Thy1.2)-coated magnetic beads and MACS columns (Miltenyi
gene. This fragment was finally cloned into the original Bi-ubi-NS3- Biotec, Auburn, CA). In other experiments, splenic low-density cells
NS5B plasmid that had been digested with NheI and XhoI (XhoI cuts were isolated by density centrifugation over a 30% BSA (Sigma-
immediately upstream of the EMCV IRES). The plasmid encoding Aldrich, St. Louis, MO) step gradient.
noncytopathic Repli-HCVNS3 RNA was generated from the previously
described Bi-NS2-NS5B cDNA construct (Tautz et al., 1999) using Visualization of Adoptively Transferred DCs
the same strategy. The plasmid pcDNA3/NS3 was generated by Draining lymph nodes and spleens were isolated and analyzed for
cloning the HCVNS3 gene of the Con1 cDNA into the BamHI and XbaI the presence of CFSE 12 hr after immunization with CFSE-labeled
sites of pcDNA3 (Invitrogen, Carlsbad, CA). DC2.4. For flow cytometry, low-density spleen cells and lymph node
cells were incubated with anti-HLA-A2.1 (ATCC, Manassas, VA) and
In Vitro Transcription of RNA biotin-conjugated anti-mouse CD11c followed by phycoerytrin (PE)-
SrfI and SmaI (Stratagene, La Jolla, CA) were used to linearize DNA conjugated anti-mouse F(ab)2 IgG (Immunotech, Marseille, France),
templates of Repl-HCVNS3 and Repl-GUS constructs, respectively. PerCP-conjugated Streptavidin (PharMingen, San Diego, CA), and
After purification with MiniElute Reaction Cleanup Kit (Qiagen Inc., allophycocyanin (APC)-conjugated anti-mouse F4/80 (PharMingen).
Valencia, CA), linearized plasmids were in vitro transcribed with SP6 Cells were analyzed on a FACSCalibur with CellQuest (Becton &
RNA polymerase (Roche Diagnostics, Indianapolis, IN) in a standard Dickinson, San Jose, CA) and FlowJo (FlowJo, San Carlos, CA)
reaction. After removal of DNA by digestion with RNase-free DNase I software. For IF, lymph node cell cytospins and spleen cryosections
(Roche Diagnostics, Indianapolis, IN) and purification of synthesized were acetone fixed, stained with PE-conjugated anti-mouse CD11c
RNA with the Rneasy Mini Kit (Qiagen Inc., Valencia, CA), RNA con- (PharMingen), counterstained with DAPI (Molecular Probes, Eugene,
centration and integrity were determined by UV spectrophotometry OR), mounted, and examined with a Zeiss Axioskop2 microscope
(OD 260 nm) and gel electrophoresis. (Carl Zeiss Inc., Thornwood, NY) equipped with an epifluores-
cence source.
RNA Transfection of DCs and Detection of HCVNS3 Expression
Five hundred thousand DC2.4 were pelleted, resuspended in Cy- ELISpot Assay
Ex vivo IFN--ELISpot assays were performed as previously de-tomix (van den Hoff et al., 1992) containing 1.25% DMSO, mixed
with 5 	g RNA, transferred to a 2 mm gap cuvette, and electro- scribed (Wedemeyer et al., 2001) with the following modifications.
Individual HCVNS3 peptide pools (1 	g/ml per peptide) or HLA-A2-shocked twice at a voltage of 300 V and a capacitance of 150 	F
using a Gene Pulser apparatus (Bio-Rad, Hercules, CA). After a 10 restricted HCVNS3 and VV peptides (10 	g/ml) were used to stimulate
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for 30 hr (a) serial dilutions of freshly purified splenic T cells in the Banchereau, J., and Steinman, R.M. (1998). Dendritic cells and the
control of immunity. Nature 392, 245–252.presence of 105 irradiated (10,000 rad) EL4 or C1R-AAD cells per
well, or (b) 2.5  105 unseparated splenocytes per well. All cultures Barnaba, V., Franco, A., Alberti, A., Benvenuto, R., and Balsano, F.
were set up in triplicates with appropriate negative (no peptide) (1990). Selective killing of hepatitis B envelope antigen-specific B
and positive (0.2 	g/ml phytohemagglutinin, Murex Biotech Limited, cells by class I restricted, exogenous antigen specific T lympho-
Dartford, England) controls. Spots were evaluated and counted with cytes. Nature 345, 258–260.
a KS ELISpot Reader (Carl Zeiss Inc., Thornwood, NY). The number
Bartenschlager, R., Ahlborn-Laake, L., Mous, J., and Jacobsen, H.
of specific spots was obtained by subtracting the mean number of
(1994). Kinetic and structural analyses of hepatitis C virus polypro-
spots in negative control wells from the mean number of spots in
tein processing. J. Virol. 68, 5045–5055.
experimental wells.
Behrens, S.E., Grassmann, C.W., Thiel, H.J., Meyers, G., and Tautz,
N. (1998). Characterization of an autonomous subgenomic pestivirus
Proliferation Assay
RNA replicon. J. Virol. 72, 2364–2372.
Triplicate cultures of 5  105 T cells were stimulated for 5 days with
Berd, D. (2001). Autologous, hapten-modified vaccine as a treatment105 irradiated (10,000 rad) EL4 cells and with either 1 	g/ml HCVNS3
for human cancers. Vaccine 19, 2565–2570.protein or buffer control or 1 	g/ml PHA in complete RPMI 1640
Bevan, M.J. (1987). Antigen recognition. Class discrimination in themedium. For the last 16 hr, 1 	Ci 3H-thymidine (ICN, Costa Mesa,
world of immunology. Nature 325, 192–194.CA) was added and the incorporated radioactivity was measured
and expressed as stimulation index (cpm in presence of antigen/ Cella, M., Salio, M., Sakakibara, Y., Langen, H., Julkunen, I., and
cpm in absence of antigen). Lanzavecchia, A. (1999). Maturation, activation, and protection of
dendritic cells induced by double-stranded RNA. J. Exp. Med.
Chromium Release Assay 189, 821–829.
Five hundred thousand purified splenic T cells were cultured with Davis, G.L., Albright, J.E., Cook, S.F., and Rosenberg, D.M. (2003).
105 irradiated (10,000 rad) EL4 or C1R-AAD cells in complete RPMI Projecting future complications of chronic hepatitis C in the United
1640 medium containing individual HCVNS3 peptide pools (1 	g/ml States. Liver Transpl. 9, 331–338.
per peptide). On day 2, 10% Rat-T-Stim (Collaborative Biomedical
den Haan, J.M., Lehar, S.M., and Bevan, M.J. (2000). CD8() but
Products, Bedford, MA) was added. On day 7, a 6 hr 51Cr-release
not CD8() dendritic cells cross-prime cytotoxic T cells in vivo. J.
assay was performed using EL4 or C1R-AAD target cells that had
Exp. Med. 192, 1685–1696.
been pulsed with individual HCVNS3 peptide pools at 1 	g/ml per
Dhodapkar, M.V., Steinman, R.M., Sapp, M., Desai, H., Fossella, C.,peptide overnight and then labeled with 100 	Ci 51Cr (Amersham)
Krasovsky, J., Donahoe, S.M., Dunbar, P.R., Cerundolo, V., Nixon,for 1 hr at 37C. Triplicate cultures of 3000 target cells were incu-
D.F., and Bhardwaj, N. (1999). Rapid generation of broad T-cellbated with effector cells. Percent specific lysis was calculated as
immunity in humans after a single injection of mature dendritic cells.(experimental release  spontaneous release)  100/(maximum
J. Clin. Invest. 104, 173–180.release  spontaneous release), in which spontaneous and maxi-
Diepolder, H.M., Zachoval, R., Hoffmann, R.M., Wierenga, A., Sant-mum release reflected target cell lysis in the absence of effector
antonio, T., Jung, M.-C., Eichenlaub, D., and Pape, G.R. (1995).cells and in the presence of 10% Triton X-100 (Sigma-Aldrich, St.
Possible mechanism involving T lymphocyte response to non-struc-Louis, MO), respectively.
tural protein 3 in viral clearance in acute hepatitis C virus infection.
Lancet 346, 1006–1007.Recombinant Vaccinia Virus Challenge and Plaque Assay
Two weeks after immunization, mice were intraperitoneally chal- Drexler, I., Staib, C., Kastenmuller, W., Stevanovic, S., Schmidt, B.,
Lemonnier, F.A., Rammensee, H.G., Busch, D.H., Bernhard, H., Erfle,lenged with 107 plaque-forming units of HCVNS3-encoding recombi-
nant vaccinia virus (VV) (Bartenschlager et al., 1994; Wedemeyer et V., and Sutter, G. (2003). Identification of vaccinia virus epitope-
specific HLA-A*0201-restricted T cells and comparative analysis ofal., 2001). Five days later, mice were sacrificed and VV titers were
determined by plating 10-fold dilutions of homogenized and soni- smallpox vaccines. Proc. Natl. Acad. Sci. USA 100, 217–222.
cated ovaries on 143TK monolayers that were stained with 0.075 Freigang, S., Egger, D., Bienz, K., Hengartner, H., and Zinkernagel,
wt/vol% crystal violet 48 hr later. R.M. (2003). Endogenous neosynthesis vs. cross-presentation of
viral antigens for cytotoxic T cell priming. Proc. Natl. Acad. Sci. USA
Statistical Analysis 100, 13477–13482.
A p value 0.05 (Mann-Whitney U test) was considered statistically Grassmann, C.W., Isken, O., Tautz, N., and Behrens, S.E. (2001).
significant. Genetic analysis of the pestivirus nonstructural coding region: de-
fects in the NS5A unit can be complemented in trans. J. Virol. 75,
Acknowledgments 7791–7802.
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